Effect of Ocrelizumab in Blood Leukocytes of Patients With Primary Progressive MS

OBJECTIVE: To analyze the changes induced by ocrelizumab in blood immune cells of patients with primary progressive MS (PPMS). METHODS: In this multicenter prospective study including 53 patients with PPMS who initiated ocrelizumab treatment, we determined effector, memory, and regulatory cells by f...

Descripción completa

Detalles Bibliográficos
Autores principales: Fernández-Velasco, José I., Kuhle, Jens, Monreal, Enric, Meca-Lallana, Virginia, Meca-Lallana, José, Izquierdo, Guillermo, Gascón-Giménez, Francisco, Sainz de la Maza, Susana, Walo-Delgado, Paulette E., Maceski, Aleksandra, Rodríguez-Martín, Eulalia, Roldán, Ernesto, Villarrubia, Noelia, Saiz, Albert, Blanco, Yolanda, Sánchez, Pedro, Carreón-Guarnizo, Ester, Aladro, Yolanda, Brieva, Luis, Íñiguez, Cristina, González-Suárez, Inés, Rodríguez de Antonio, Luis A., Masjuan, Jaime, Costa-Frossard, Lucienne, Villar, Luisa M.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Lippincott Williams & Wilkins 2021
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7862094/
https://www.ncbi.nlm.nih.gov/pubmed/33408167
http://dx.doi.org/10.1212/NXI.0000000000000940

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7862094/
https://www.ncbi.nlm.nih.gov/pubmed/33408167
http://dx.doi.org/10.1212/NXI.0000000000000940

Ejemplares similares